Additional investigations on extracellular tau interaction with clusterin (which is mostly extracellular) and cell-type specific functional characterisations of intracellular interactions between clusterin and tau are needed to understand how rare AD-associated CLU variants may modulate later stages of disease progression. This evidence concerns the gene MAPT and Alzheimer disease.